主催: 日本臨床薬理学会
In this talk, I will introduce model informed drug discovery, development, andutilization (MIDD), including recent examples, and will discuss the challengesand opportunities that the new era of artificial intelligence and machinelearning (AI/ML) offers to clinical pharmacology and therapeutics. I also willprovide an introduction to the International Society of Pharmacometrics (ISoP)and its role in advancing the science and impact of MIDD. As part of the lattertopic, I will discuss highlights from the two recent joint FDA-ISoP Workshops onquantitative methods in dosage optimization of oncology products.